EVH Evolent Health, Inc.
Services-Management Services · NYSE · SEC CIK 1628908 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY14.1%
TTM net income YoY-296.1%
TTM EPS YoY-187.3%
Revenue 3-yr CAGR9.4%
Net income 3-yr CAGR—
Margins
Gross margin15.0%
Operating margin-18.5%
Net margin-21.7%
FCF margin—
EBITDA margin-13.9%
Returns
ROE-83.6%
ROA-23.0%
ROIC (approx.)-23.0%
Asset turnover1.06x
Leverage & solvency
Liabilities / assets81.0%
Debt / equity2.60x
Current ratio1.26x
Interest coverage-6.23x
Cash quality & payout
Operating cash flow / net income-0.13x
Accruals ratio-25.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $1.88B | $2.55B |
| Cost of revenue | $1.48B | $2.19B |
| Gross profit | $399.88M | $367.35M |
| SG&A expense | $303.87M | $263.05M |
| Operating income | -$410.14M | -$40.48M |
| Interest expense | $57.47M | $24.72M |
| Pretax income | -$534.64M | -$63.04M |
| Income tax | -$126,000 | -$1.41M |
| Net income | -$534.51M | -$61.62M |
| EBITDA | -$294.29M | $77.89M |
| EPS (basic) | -5.07 | -0.81 |
| EPS (diluted) | -5.07 | -0.81 |
| Weighted avg. shares (diluted) | 114.21M | 114.68M |
| Balance sheet | ||
| Cash & equivalents | $151.86M | $178.50M |
| Receivables | $309.86M | $414.68M |
| Current assets | $506.37M | $607.12M |
| PP&E, net | $80.78M | $73.15M |
| Goodwill | $694.48M | $1.14B |
| Intangibles | $584.94M | $680.16M |
| Total assets | $1.90B | $2.54B |
| Current liabilities | $385.26M | $715.50M |
| Short-term debt | $0 | $171.47M |
| Long-term debt | $970.54M | $490.52M |
| Total debt | $970.54M | $661.99M |
| Total liabilities | $1.48B | $1.35B |
| Shareholders' equity | $415.19M | $1.00B |
| Net debt | $818.68M | $483.49M |
| Cash flow statement | ||
| Operating cash flow | $38.84M | $18.77M |
| Investing cash flow | -$233,000 | -$62.93M |
| Financing cash flow | -$35.92M | -$565,000 |
| Depreciation & amortization | $115.85M | $118.37M |
| Stock-based compensation | $39.74M | $39.75M |
| Share buybacks | $40.00M | $0 |
Free plan shows the latest 2 periods; Pro shows all 13 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.